Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)

被引：0
|
作者：
Singh, Abhay
Gravina, Matthew
Tajammal, Rutaba
Nowak, Annmarie
Iyer, Renuka
Faber, Mark G.
Yan, LunBiao
Hassane, Duane C.
Guzman, Monica L.
Mencia-Trinchant, Nuria
Wang, Eunice S.
Thota, Swapna
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141570
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors
    El Ferkh, R.
    Hadoux, J.
    Lamartina, L.
    Kamoun, T.
    Cysique-Foinlan, L.
    Jepiral, G.
    Ducreux, M. P.
    Baudin, E.
    Marzac, C.
    Micol, J. Baptiste
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S954 - S955
  • [2] Safety in Patients With Neuroendocrine Tumors Receiving Telotristat Ethyl (TE) With Peptide Receptor Radionuclide Therapy (PRRT)
    Chauhan, A.
    Binder, P.
    Tesfaye, E.
    Seth, K.
    Lapuerta, P.
    [J]. PANCREAS, 2021, 50 (03) : 447 - 448
  • [3] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
    Bodei, L.
    Pepe, G.
    Paganelli, G.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
  • [4] Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)
    Otte, Andreas
    [J]. HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (02): : 182 - 182
  • [5] Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)
    Papamichail, Dimitris G.
    Exadaktylou, Paraskevi E.
    Chatzipavlidou, Vasiliki D.
    [J]. HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (01): : 75 - 83
  • [6] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
    Duan, H.
    Girod, B.
    Ninatti, G.
    Ferri, V
    Kunz, P.
    Fisher, G.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Lagaru, A.
    Aparici, Mari C.
    [J]. NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
  • [7] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
  • [8] Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Metastatic Neuroendocrine Tumors: How Effective and Safe Are They?
    Liotsou, T.
    Stefanoyiannis, A. P.
    Chatziioannou, S. N.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S725 - S726
  • [9] Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)
    Norman, A.
    Wee, C.
    Hobday, T.
    Kendi, A.
    Johnson, G.
    Thorpe, M.
    Lunn, B.
    Bach, C.
    Eiring, R.
    Halfdanarson, T.
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 192 - 192
  • [10] Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Metastatic Low Grade Neuroendocrine Tumors (mNETs)
    Naraev, Boris G.
    Sharma, Nancy
    Engelman, Eric S.
    Bushnell, David L., Jr.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur R.
    [J]. PANCREAS, 2012, 41 (02) : 347 - 348
12345